卡瑞利珠单抗联合安罗替尼治疗鼻咽癌1例

[1]	Taylor MH, Lee CH, Makker V, et al. PhaseⅠB/Ⅱ trial of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma, endometrial cancer, and other selected advanced solid tumors[J]. J Clin Oncol, 2020, 38(11):1154-1163. doi: 10.1200/JCO.19.01598
[2]	Wang YQ, Chen YP, Zhang Y, et al. Prognostic significance of tumorinfiltrating lymphocytes in nondisseminated nasopharyngeal carcinoma:A large-scale cohort study[J]. Int J Cancer, 2018, 142(12):2558-2566. doi: 10.1002/ijc.31279
[3]	Chow JC, Ngan RK, Cheung KM, et al. Immunotherapeutic approaches in nasopharyngeal carcinoma[J]. Expert Opin Biol Ther, 2019, 19(11):1165-1172. doi: 10.1080/14712598.2019.1650910
[4]	Fang W, Yang Y, Ma Y, et al. Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma:results from two single-arm, phase 1 trials[J]. Lancet Oncol, 2018, 19(10):1338-1350. doi: 10.1016/S1470-2045(18)30495-9